Author

Sabyasachi Das

Dana-Farber/Boston Children's Cancer and Blood Disorders CenterORCID 0000-0002-6243-2058Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Sabyasachi Das2 papers · Harvard University

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Alessandra BiffiiD· 1 shared Ana Zguro· 1 shared Benjamin P. KleinstiveriD· 1 shared C.K. Fong· 1 shared Casey A. MaguireiD· 1 shared Christian Lacks Lino CardenasiD· 1 shared Christiano R. R. AlvesiD· 1 shared Claire E. ShamberiD· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperNeuroscience

Alessandra BiffiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioengineeringNature Biomedical EngineeringPeer-reviewedSep 11, 2025

In vivo Treatment of a Severe Vascular Disease via a Bespoke CRISPR-Cas9 Base Editor

Christiano R. R. Alves, Sabyasachi Das, Vijai Krishnan…·Patricia Leonor Musolino

This paper develops a customized CRISPR-Cas9 base editor to correct the ACTA2 R179H mutation in a mouse model of MSMDS, improving survival and rescuing vascular and neurological phenotypes.

13 citations

mousegenetic perturbation / CRISPR

𝕏 PostBluesky

NeuroscienceEMBO Molecular MedicinePeer-reviewedMar 6, 2023

An innovative hematopoietic stem cell gene therapy approach benefits CLN1 disease in the mouse model

Marco Peviani, Sabyasachi Das, Janki Patel…·Alessandra Biffi

This study demonstrates that gene therapy using hematopoietic stem cells can mitigate CLN1 disease symptoms in mice, with enhanced benefits from hPPT1 overexpression and combined transplantation approaches.

10 citations

mouseexperimental assay

𝕏 PostBluesky